JP2014505049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505049A5 JP2014505049A5 JP2013547780A JP2013547780A JP2014505049A5 JP 2014505049 A5 JP2014505049 A5 JP 2014505049A5 JP 2013547780 A JP2013547780 A JP 2013547780A JP 2013547780 A JP2013547780 A JP 2013547780A JP 2014505049 A5 JP2014505049 A5 JP 2014505049A5
- Authority
- JP
- Japan
- Prior art keywords
- ccr2
- pharmaceutically acceptable
- acceptable salt
- angiotensin receptor
- pathway inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011900060 | 2011-01-11 | ||
| AU2011900060A AU2011900060A0 (en) | 2011-01-11 | Combination Therapy | |
| AU2011904279A AU2011904279A0 (en) | 2011-10-17 | Combination Therapy | |
| AU2011904279 | 2011-10-17 | ||
| PCT/AU2012/000014 WO2012094703A1 (en) | 2011-01-11 | 2012-01-11 | Combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016247754A Division JP2017078085A (ja) | 2011-01-11 | 2016-12-21 | 併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014505049A JP2014505049A (ja) | 2014-02-27 |
| JP2014505049A5 true JP2014505049A5 (cg-RX-API-DMAC7.html) | 2015-02-19 |
| JP6087836B2 JP6087836B2 (ja) | 2017-03-01 |
Family
ID=46506697
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547780A Active JP6087836B2 (ja) | 2011-01-11 | 2012-01-11 | 併用療法 |
| JP2016247754A Pending JP2017078085A (ja) | 2011-01-11 | 2016-12-21 | 併用療法 |
| JP2018101282A Pending JP2018127498A (ja) | 2011-01-11 | 2018-05-28 | 併用療法 |
| JP2020084905A Pending JP2020122015A (ja) | 2011-01-11 | 2020-05-14 | 併用療法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016247754A Pending JP2017078085A (ja) | 2011-01-11 | 2016-12-21 | 併用療法 |
| JP2018101282A Pending JP2018127498A (ja) | 2011-01-11 | 2018-05-28 | 併用療法 |
| JP2020084905A Pending JP2020122015A (ja) | 2011-01-11 | 2020-05-14 | 併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US9314450B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2663304B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6087836B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107899012A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012206945B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2821985C (cg-RX-API-DMAC7.html) |
| IL (1) | IL227414A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012094703A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201305897B (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2793657A1 (en) | 2010-03-18 | 2011-09-22 | Colorado State University Research Foundation | Myeloid derived suppressor cell inhibiting agents |
| EP2726108B1 (en) | 2011-06-29 | 2018-01-10 | The Trustees of Columbia University in the City of New York | Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction |
| WO2014021942A1 (en) * | 2012-08-01 | 2014-02-06 | University Of Southern California | Methods for limiting development of neurodegeneration |
| WO2014075096A1 (en) * | 2012-11-09 | 2014-05-15 | The Trustees Of Columbia University In The City Of New York | Inhibitors of central nervous system vasoactive inhibitory peptide receptor 2 |
| TW201442706A (zh) | 2013-02-28 | 2014-11-16 | 參天製藥股份有限公司 | 含有四氫吡喃基胺基環戊基羰基四氫吡啶并吡啶衍生物作爲有效成分之後眼部疾病之預防或治療劑 |
| US8975290B2 (en) | 2013-03-01 | 2015-03-10 | Colorado State University Research Foundation | Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis |
| WO2014134621A2 (en) * | 2013-03-01 | 2014-09-04 | Colorado State University Research Foundation | Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis |
| CN103193771B (zh) * | 2013-03-29 | 2015-08-05 | 中国人民解放军军事医学科学院生物工程研究所 | 链状酰胺类ccr5受体抑制剂的药物新用途 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US10561676B2 (en) * | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| TW201625255A (zh) * | 2014-07-17 | 2016-07-16 | 參天製藥股份有限公司 | 後眼部疾病之預防或治療劑 |
| EP3191100A4 (en) * | 2014-09-12 | 2018-05-30 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| MX2018003179A (es) * | 2015-09-16 | 2018-08-21 | Tobira Therapeutics Inc | Terapia de combinación con cenicriviroc para el tratamiento de fibrosis. |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| CN109069486A (zh) | 2015-12-14 | 2018-12-21 | X4 制药有限公司 | 治疗癌症的方法 |
| PT3393468T (pt) | 2015-12-22 | 2023-01-19 | X4 Pharmaceuticals Inc | Métodos para tratar imunodeficiências |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| WO2017223239A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| CN109641838A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| AU2017363299B2 (en) * | 2016-11-23 | 2022-12-22 | Chemocentryx, Inc. | Method of treating focal segmental glomerulosclerosis |
| SG11202002975YA (en) | 2017-10-11 | 2020-04-29 | Chemocentryx Inc | Treatment of focal segmental glomerulosclerosis with ccr2 antagonists |
| CN108218789A (zh) * | 2018-03-12 | 2018-06-29 | 钦州学院 | 碳13氘代甲基替米沙坦及其制备方法和用途 |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| CA3135694A1 (en) * | 2019-04-17 | 2020-10-22 | Hiroshima University | Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination |
| US20240009191A1 (en) * | 2019-09-26 | 2024-01-11 | Dimerix Bioscience Pty Ltd | Method and composition for the treatment of disease |
| WO2021183650A1 (en) | 2020-03-10 | 2021-09-16 | X4 Pharmaceuticals, Inc. | Methods for treating neutropenia |
| GB202006079D0 (en) * | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
| EP4146191A1 (en) * | 2020-05-06 | 2023-03-15 | Dimerix Bioscience Pty Ltd | Treatment for acute respiratory distress syndrome |
| WO2021222971A1 (en) * | 2020-05-06 | 2021-11-11 | Dimerix Bioscience Ltd | Treatment for virus induced acute respiratory distress syndrome |
| EP4313024A4 (en) * | 2021-03-23 | 2025-01-08 | Dimerix Bioscience Pty Ltd | Treatment of inflammatory diseases |
| WO2024026528A1 (en) * | 2022-08-02 | 2024-02-08 | Dimerix Bioscience Pty Ltd | Dosage regimen for the treatment of copd |
| TW202444344A (zh) * | 2023-05-12 | 2024-11-16 | 澳大利亞商迪美力士生物科技有限公司 | 用於腎病之治療調配物 |
| CN117054652B (zh) * | 2023-08-04 | 2024-05-17 | 南京医科大学 | 一种用于辅助检测心肌肥厚的生物标志物及其应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| CH671155A5 (cg-RX-API-DMAC7.html) | 1986-08-18 | 1989-08-15 | Clinical Technologies Ass | |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5821232A (en) * | 1990-05-11 | 1998-10-13 | Pfizer Inc. | Synergistic therapeutic compositions and methods |
| US5492904A (en) | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
| JPH059116A (ja) | 1991-07-01 | 1993-01-19 | Sanwa Kagaku Kenkyusho Co Ltd | ３−オキシゲルミルプロピオン酸組成物並びに該組成物を主成分とする細胞変性抑制剤 |
| ES2175098T3 (es) | 1995-06-07 | 2002-11-16 | Searle & Co | Terapia de combinacion de espironolactona y antagonista de angiotensina hi para el tratamiento del fallo cardiaco congestivo. |
| US5891646A (en) | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
| EP1137940A4 (en) | 1998-10-23 | 2004-06-02 | Glaxo Group Ltd | METHOD FOR IDENTIFYING LIGANDS OF NUCLEAR RECEPTORS |
| CA2399080C (en) * | 2000-02-03 | 2013-05-21 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
| US6893827B1 (en) | 2000-02-07 | 2005-05-17 | Applera Corporation | Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation |
| CA2456754A1 (en) * | 2001-08-08 | 2003-02-20 | Yuji Iizawa | Benzazepine derivative, process for producing the same, and use |
| DE10218785A1 (de) | 2002-04-26 | 2003-11-13 | Infineon Technologies Ag | Halbleiterspeichereinrichtung und Betriebsverfahren für eine Halbleiterspeichereinrichtung |
| JP2004093527A (ja) | 2002-09-04 | 2004-03-25 | Center For Advanced Science & Technology Incubation Ltd | 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法 |
| EP1481996A1 (en) | 2003-05-30 | 2004-12-01 | KRATON Polymers Research B.V. | Process for making a coupled block copolymer composition |
| CA2531698A1 (en) | 2003-07-09 | 2005-01-27 | Sentigen Biosciences, Inc. | Method for assaying protein-protein interaction |
| US7488583B2 (en) | 2003-09-25 | 2009-02-10 | Odyssey Thera, Inc. | Fragment complementation assays for G-protein-coupled receptors and their signaling pathways |
| US20080108128A1 (en) | 2003-11-19 | 2008-05-08 | Eidne Karin A | Resonance Energy Transfer Assay System for Multi-Component Detection |
| JP2006008568A (ja) | 2004-06-24 | 2006-01-12 | Cyclochem:Kk | ＩｇＥ抗体抑制剤および食品 |
| JPWO2006028007A1 (ja) * | 2004-09-06 | 2008-05-08 | 興和株式会社 | 糸球体疾患治療剤 |
| GT200500246A (es) | 2004-09-09 | 2006-04-17 | Combinacion de compuestos organicos | |
| GB0612630D0 (en) * | 2006-06-26 | 2006-08-02 | Novartis Ag | Organic compounds |
| CN101535830B (zh) | 2006-11-10 | 2013-07-17 | 皇家飞利浦电子股份有限公司 | 预防磁共振检查系统中的失超 |
| EP2605015A1 (en) | 2006-11-10 | 2013-06-19 | Dimerix Bioscience Pty.Ltd. | Kits for determining the interaction of a test compound with two associated receptors |
| CN101534824A (zh) | 2006-11-17 | 2009-09-16 | 艾博特公司 | 作为化学活素受体拮抗剂的氨基吡咯烷 |
| WO2008113095A1 (en) * | 2007-03-20 | 2008-09-25 | Fibrotech Therapeutics Pty Ltd | Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb) |
| CN101808515A (zh) * | 2007-09-25 | 2010-08-18 | 雅培制药有限公司 | 作为趋化因子受体拮抗剂的八氢并环戊二烯化合物 |
| US20110009482A1 (en) * | 2007-12-04 | 2011-01-13 | Schering Corporation | Methods of treating copd |
| ES2395002T3 (es) | 2008-04-07 | 2013-02-07 | Cardoz Ab | Nueva combinación para uso en el tratamiento de trastornos inflamatorios |
| JP2012510511A (ja) | 2008-12-01 | 2012-05-10 | インヴアスク セラピューテイックス インコーポレイテッド | レニン−アンジオテンシン−アルドステロン系阻害剤及びリポ酸化合物を含有する組成物、並びに、レニン−アンジオテンシン−アルドステロン系に関連した疾患の治療のためのそれらの使用 |
| US8537791B2 (en) | 2009-01-20 | 2013-09-17 | Lg Electronics Inc. | Method and apparatus for channel access in contention-based communication system and station |
| WO2010108232A1 (en) * | 2009-03-27 | 2010-09-30 | Dimerix Bioscience Pty Ltd | Novel receptor hetero-dimers/-oligomers |
-
2012
- 2012-01-11 WO PCT/AU2012/000014 patent/WO2012094703A1/en not_active Ceased
- 2012-01-11 AU AU2012206945A patent/AU2012206945B2/en active Active
- 2012-01-11 EP EP12734251.7A patent/EP2663304B1/en active Active
- 2012-01-11 EP EP19186903.1A patent/EP3586844A1/en not_active Withdrawn
- 2012-01-11 JP JP2013547780A patent/JP6087836B2/ja active Active
- 2012-01-11 CA CA2821985A patent/CA2821985C/en active Active
- 2012-01-11 EP EP23161550.1A patent/EP4215194A1/en active Pending
- 2012-01-11 CN CN201711107879.XA patent/CN107899012A/zh active Pending
- 2012-01-11 CN CN201280004616.5A patent/CN103476410B/zh active Active
- 2012-01-11 US US13/979,127 patent/US9314450B2/en active Active
-
2013
- 2013-07-10 IL IL227414A patent/IL227414A/en active IP Right Grant
- 2013-08-06 ZA ZA2013/05897A patent/ZA201305897B/en unknown
-
2016
- 2016-03-31 US US15/086,823 patent/US10058555B2/en active Active
- 2016-12-21 JP JP2016247754A patent/JP2017078085A/ja active Pending
-
2017
- 2017-09-14 US US15/704,713 patent/US10525038B2/en active Active
-
2018
- 2018-05-28 JP JP2018101282A patent/JP2018127498A/ja active Pending
-
2019
- 2019-10-16 US US16/654,912 patent/US11382896B2/en active Active
-
2020
- 2020-05-14 JP JP2020084905A patent/JP2020122015A/ja active Pending
-
2022
- 2022-05-11 US US17/662,866 patent/US12083102B2/en active Active
-
2024
- 2024-07-16 US US18/774,024 patent/US20240366570A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014505049A5 (cg-RX-API-DMAC7.html) | ||
| Michel et al. | A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists | |
| JP2018507244A5 (cg-RX-API-DMAC7.html) | ||
| JP6087836B2 (ja) | 併用療法 | |
| JP2014526492A5 (cg-RX-API-DMAC7.html) | ||
| DK3027183T3 (en) | SELECTIVE AT2 RECEPTOR AGONISTS FOR USING CACKSY TREATMENT | |
| CN1312715A (zh) | 缬沙坦和钙通道阻断剂的抗超敏组合 | |
| EP2328414A4 (en) | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | |
| CO6180425A2 (es) | Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos | |
| JP2020536919A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512817A5 (cg-RX-API-DMAC7.html) | ||
| JP2017520562A5 (cg-RX-API-DMAC7.html) | ||
| Morganti et al. | Aliskiren: the first direct renin inhibitor available for clinical use | |
| JP2016538295A5 (cg-RX-API-DMAC7.html) | ||
| Riva et al. | Which is the optimal antihypertensive combination in different diseases, a renin-angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker? | |
| CN1249682A (zh) | 用于治疗有症状的心力哀竭的血管紧张素ⅱ拮抗剂 | |
| CA2798573A1 (en) | Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof | |
| JP2018521077A5 (cg-RX-API-DMAC7.html) | ||
| RU2016103099A (ru) | Способ предотвращения и/или лечения хронической травматической энцефалопатии - i | |
| Parvanova et al. | Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade | |
| Destro et al. | Olmesartan medoxomil: recent clinical and experimental acquisitions | |
| Kim et al. | Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer | |
| Hou et al. | Optimal dose of angiotensin‐converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection | |
| Vaněčková et al. | Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade | |
| JP2016505628A5 (cg-RX-API-DMAC7.html) |